BIOIMAGE-NMD

BIOIMAGE-Neuromuscular Diseases

Coordinatore	UNIVERSITY OF NEWCASTLE UPON TYNE    more  Organization address address: Kensington Terrace 6 city: NEWCASTLE UPON TYNE postcode: NE1 7RU contact info Titolo: Mrs. Nome: Helen Cognome: Gallon Email: send email Telefono: +44 0 1912824513
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	7˙838˙853 €
EC contributo	5˙960˙532 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2017-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF NEWCASTLE UPON TYNE  Organization address address: Kensington Terrace 6 city: NEWCASTLE UPON TYNE postcode: NE1 7RU contact info Titolo: Mrs. Nome: Helen Cognome: Gallon Email: send email Telefono: +44 0 1912824513	UK (NEWCASTLE UPON TYNE)	coordinator	1˙452˙729.20
2	BIOMARIN NEDERLAND BV  Organization address address: J H OORTWEG 21 city: LEIDEN postcode: 2333 CH contact info Titolo: Dr. Nome: Isabel Cognome: Ferreira Email: send email Telefono: 31614790205 Fax: 31713322088	NL (LEIDEN)	participant	1˙128˙014.00
3	ASSOCIATION INSTITUT DE MYOLOGIE  Organization address address: BOULEVARD DE L HOPITAL 47-83 city: PARIS postcode: 75651 contact info Titolo: Mrs. Nome: Christelle Cognome: Gaultier Email: send email Telefono: +33 14216 66 46	FR (PARIS)	participant	1˙044˙498.00
4	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Gosia Cognome: Kielbasa Email: send email Telefono: +44 2031083033 Fax: +44 20 78132849	UK (LONDON)	participant	591˙293.00
5	SCITO SA  Organization address address: RUE DES HAIES 8 city: PARIS postcode: 75020 contact info Titolo: Dr. Nome: Arno Cognome: Klaassen Email: send email Telefono: +33 971279191	FR (PARIS)	participant	571˙266.80
6	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Jan Cognome: Verschuuren Email: send email Telefono: +31 715262197	NL (LEIDEN)	participant	531˙492.00
7	CONSULTANTS FOR RESEARCH IN IMAGING AND SPECTROSCOPY SCRL  Organization address address: RUE LOUIS JAMME 24 city: LIEGE postcode: 4020 contact info Titolo: Dr. Nome: Raymond Cognome: Gilles Email: send email Telefono: +31 14790205	BE (LIEGE)	participant	399˙800.00
8	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Elke Cognome: Lammertyn Email: send email Telefono: +32 16 32 06 21	BE (LEUVEN)	participant	120˙720.00
9	UNIVERSITA CATTOLICA DEL SACRO CUORE  Organization address address: Largo Agostino Gemelli 1 city: MILANO postcode: 20123 contact info Titolo: Mr. Nome: Filippo Cognome: Leone Email: send email Telefono: +39 0630156099	IT (MILANO)	participant	120˙720.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'BIOIMAGE-NMD will develop and apply imaging technology to monitor response to novel therapies in neuromuscular diseases (NMD) and will use Duchenne muscular dystrophy (DMD) as an exemplar disease. DMD is well characterised genetically and clinically but to date a disease modifying treatment is not available. One of the most promising developments for future treatment of NMD is RNA modulation through antisense oligonucleotides (AON). In DMD, AON are used for exon skipping and this is a genuine example of personalised medicine, where patients are treated according to their specific gene mutation. Quantitative Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopic Imaging (MRSI) are used to assess structural and metabolic muscle pathology in NMD but their effectiveness in monitoring therapy is yet to be shown. The project will apply a simultaneous MRI/MRSI protocol in multi-centre clinical trials of AON therapy in DMD with the aim of establishing a clinical proof of principle that these imaging measures are effective biomarkers of therapeutic response. To enhance the imaging protocol, novel Diffusion Tensor MRI (DTI) methods will be developed and optimised to assess muscle microstructure and applied in these trials. The project will also develop methods for radiolabelling of AON and demonstrate the use of pre-clinical Positron Emission Tomography (PET)/MRI to assess the tissue targeting, bio-distribution and pharmacokinetics of AON in vivo. BIOIMAGE-NMD will deliver PET/MRI and MRI/MRSI technologies for both drug development and clinical evaluation roles which will significantly contribute to bringing personalized therapeutic interventions in rare and common diseases to the market.'